FDA's July 2024 Roundup: Breakthroughs and Milestones in Cancer Treatment
Here is a look back on all the FDA happenings from the month of July 2024.
July 2024 proved to be a landmark month for the FDA, with significant approvals, fast track designations, and key submissions. Notably, the FDA approved the FoundationOne Liquid CDx as a companion diagnostic for niraparib (Zejula) and abiraterone acetate (Akeega) in patients with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC), as well as Guardant Shield, a blood test to detect cancer in the colon or rectum.
The FDA granted 6 fast track designations, including one to OBX-115, an innovative therapy for advanced melanoma that has relapsed or is refractory to PD-1/PD-L1 inhibitors. A regenerative medicine advanced therapy (RMAT) designation was granted to AIC100 for recurrent anaplastic thyroid cancer and is expected to expedite the development of this novel chimeric antigen receptor (CAR) T-cell therapy.
Two biologics license applications were also accepted by the FDA, including 1 for remestemcel-L (Ryoncil) for pediatric steroid-refractory acute graft-vs-host disease (SR-aGVHD) and 1 for tabelecleucel (tab-cel; Ebvallo) for the treatment of Epstein-Barr virus-positive posttransplant lymphoproliferative disease.
On July 25, the FDA’s Oncologic Drugs Advisory Committee (ODAC) met and voted to require comprehensive phase assessments for new trial designs in perioperative regimens for non–small cell lung cancer (NSCLC). The goal of this decision is to improve the evaluation of treatment efficacy and safety in NSCLC, with the hopes of potentially improving outcomes for patients who are undergoing surgery.
Here is a look back on all the FDA happenings from the month of July 2024.
FDA Approves FoundationOne Liquid CDx for Niraparib/Abiraterone in Aggressive Prostate Cancer
On July 1, 2024, FoundationOne Liquid CDx became an FDA-approved companion device for niraparib and abiraterone acetate in deleterious or suspected deleterious BRCA-mutated mCRPC.
DNA Molecule : © ktsdesign - stock.adobe.com
Cosibelimab BLA Resubmitted to FDA for Metastatic cSCC
The biologics license application of cosibelimab (formerly CK-301) for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) was resubmitted to the FDA on July 2, 2024.
FDA Fast Tracks 225Ac-FL-020 in mCRPC
A fast track designation was granted to 225Ac-FL-020 on July 2, 2024, for the treatment of mCRPC.
FDA Clears IND of Intravenous JCXH-211 in Advanced Solid Tumors
The FDA granted clearance to an investigational new drug (IND) application of intravenous JCXH-211 in patients with advanced solid tumors on July 8, 2024.
ADI-270 Gains FDA Fast Track Status in Metastatic/Advanced ccRCC
Also on July 8, 2024, a fast track designation was given to ADI-270 from the FDA for treating metastatic or advanced clear cell renal cell carcinoma (ccRCC) previously treated with an immune checkpoint inhibitor and a VEGF inhibitor.
BLA for Remestemcel-L to Treat Pediatric SR-aGVHD Resubmitted to FDA
The biologics license application for remestemcel-L for the treatment of pediatric patients with SR-aGVHD was resubmitted to the FDA on July 9, 2024.
FDA Wraps Up End of Phase 2 Meeting for AML Combination Therapy
The end of phase 2 meeting between the FDA and Moleculin Biotech, Inc. for the phase 1b/2 trial (NCT05319587) of the combination of annamycin and cytarabine in patients with acute myeloid leukemia (AML) was completed on July 10, 2024.
FDA Receives 505(b)(2) NDA Seeking Approval for Lutetium Lu 177 Dotatate
On July 9, 2024, a 505(b)(2) new drug application seeking the approval of Curium’s formulation of lutetium Lu 177 dotatate injection for treating somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors was submitted to the FDA.
FDA Fast Tracks Innovative TIL Therapy OBX-115 in Advanced Melanoma
The FDA granted a fast track designation to OBX-115 on July 9, 2024, for the treatment of metastatic melanoma that is refractory to or relapsed following treatment with PD-1/PD-L1–based immune checkpoint inhibitors.
FDA Enforces Partial Hold on Trial of Seclidemstat in MDS/CMML
A partial clinical hold was placed on a phase 1 trial (NCT04734990) of the combination of seclidemstat (SP-2577) with azacitidine in myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML), also on July 9, 2024.
FDA Receives IND Submission for Phase 1/2 Trial of Silmitasertib in Solid Tumors
An IND application for a phase 1/2 trial of silmitasertib (CX-4945) plus chemotherapy in pediatric and young adult patients with relapsed/refractory solid tumors was submitted to the FDA on July 11, 2024.
Medical illustration featuring cancer cells from a microscopic to macroscopic view, illuminated by neon lights to enhance visual clarity and focus: © Fay Melronna - stock.adobe.com
FDA Fast Tracks DSP-5336 in NPM1/KMT2A+ Acute Leukemia
On July 15, 2024, the FDA granted DSP-5336 a fast track designation, supported by updated findings from an ongoing phase 1/2 study in relapsed/refractory AML with a KMT2A rearrangement, also known as mixed lineage leukemia rearrangement or NPM1 mutation.
FDA Fast Tracks Novel Dendritic Cell Vaccine for Pancreatic Cancer
Also on July 15, 2024, the FDA granted a fast track designation for DOC1021 for the treatment of pancreatic ductal adenocarcinoma.
FDA Grants Rare Pediatric Disease Designation to SLS009 in Pediatric AML
The FDA granted SLS009 (formerly GFH009) a rare pediatric disease designation for the treatment of pediatric patients with AML on July 16, 2024.
FDA Grants Orphan Drug Designation to Novel B7-H3-Targeting ADC in SCLC
Also on July 16, 2024, the FDA granted 7MW3711 an orphan drug designation for the treatment of small cell lung cancer.
FDA Accepts Application of Tab-Cel, First-in-Class Therapy for EBV+ PTLD
On July 17, 2024, the FDA accepted and granted priority review to the biologics license application of tab-cel for the treatment of Epstein-Barr virus-positive posttransplant lymphoproliferative disease.
Phase 3 Trials of Botensilimab/Balstilimab Move Forward, Despite FDA's Approval Setback
During an end of phase 2 meeting between the FDA and Agenus, the FDA advised against filing for accelerated approval of botensilimab (AGEN1181) combined with balstilimab (AGEN2034) for the treatment of relapsed/refractory microsatellite stable metastatic colorectal cancer without liver metastases as the objective response rates observed in the phase 2 trial (NCT05608044) of the combination may not translate to a survival benefit. This was on July 18, 2024.
FDA Clears IND of ZW191, Novel Folate Receptor Alpha-Targeting ADC
The FDA cleared the investigational new drug application for ZW191, a novel antibody-drug conjugate (ADC) on July 22, 2024.
New CAR T Granted FDA RMAT Designation for Anaplastic Thyroid Cancer
The FDA granted AIC100 RMAT designation on July 23, 2024, for the treatment of recurrent anaplastic thyroid cancer.
FDA Approves Second Dose of CAR T-Cell Therapy in Ovarian Cancer Trial
An individual patient IND application that allows for the second dose of a CAR T-cell therapy was approved by the FDA, also on July 23, 2024.
FDA Accepts Remestemcel-L BLA Resubmission for Acute GVHD
On July 23, 2024, the FDA also accepted the resubmitted biologics license application of remestemcel-L for the treatment of pediatric patients with SR-aGVHD.
FDA Fast Tracks Ozuriftamab Vedotin in Recurrent/Metastatic HNSCC
A fast track designation was granted to ozuriftamab vedotin (CAB-ROR2-ADC; BA3021) from the FDA for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) on July 23, 2024.
FDA Accepts NDA of TLX007-CDx in Prostate Cancer
The FDA accepted the filing of a new drug application (NDA) for TLX007-CDx on July 24, 2024.
Tumor microenvironment concept with cancer cells: © catalin - stock.adobe.com
FDA ODAC Votes Unanimously to Mandate Phase Assessments in NSCLC Perioperative Regimens
In an 11 to 0 vote, the FDA’s ODAC agreed on July 25, 2024, that the FDA should mandate that new trial design proposals for perioperative regimens for resectable NSCLC include an adequate trial assessment of the contribution of each treatment phase.
New CAR T Therapy for ALL Earns FDA Orphan and Rare Pediatric Drug Designations
The FDA granted orphan drug and rare pediatric disease designations to UCART22 for the treatment of acute lymphoblastic leukemia on July 25, 2024.
SenoVax Investigational New Drug Application Filed With the FDA in NSCLC
An IND application for SenoVax was filed with the FDA for the potential treatment of patients with NSCLC on July 26, 2024.
FDA Approves Shield Blood Test for Colorectal Cancer Screening
On July 19, 2024, the FDA approved Guardant Shield, a blood test to detect cancer in the colon or rectum.
Asciminib Gains FDA Priority Review in Newly Diagnosed CML
Also on July 29, 2024, the FDA granted priority review to the application of asciminib (Scemblix) for the treatment of newly diagnosed Philadelphia chromosome-positive, chronic phase chronic myeloid leukemia (CML).
FDA Clears COM503 IND in Solid Tumors, Phase 1 Trial Anticipated
On July 29, 2024, the FDA also cleared the IND application to begin a phase 1 study for COM503, a potential first-in-class treatment for solid tumors.
FDA Extends PDUFA Date for Revumenib NDA for KMT2A-Rearranged Acute Leukemia
The Prescription Drug User Fee Act target action date for the new drug application for revumenib (SNDX-5613) was extended by the FDA on July 29, 2024, to December 26, 2024.
Promising Pancreatic Cancer Treatment Receives FDA Orphan Drug Designation
On July 29, 2024, the FDA also granted an orphan drug designation to avutometinib (VS-6766) plus defactinib (VS-6063) for the treatment of pancreatic cancer.
FDA Approves Daratumumab Plus VRd in Newly Diagnosed Multiple Myeloma
On July 30, 2024, daratumumab and hyaluronidase-fihj regimen (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (D-VRd) was approved by the FDA for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
FDA Clears IND Application of UB-VV111 in Hematologic Malignancies
The FDA cleared the IND application for UB-VV111 for the potential treatment of hematologic malignancies on July 31, 2024.
FDA Grants VCN-01 Rare Pediatric Disease Designation in Retinoblastoma
The FDA also granted rare pediatric disease designation to VCN-01 for the treatment of retinoblastoma on July 31, 2024.
The FDA accepted darolutamide’s application for metastatic hormone-sensitive prostate cancer, imatinib is now in liquid form, and ribociclib, combined with an NSAI, showed significant benefit in high-risk, node-negative early-stage breast cancer. Brexu-cel demonstrated CNS remission in relapsed/refractory B-ALL, and a new vaccine shows promise in breast cancer.
Read More
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
Improving the Transition From Inpatient to Outpatient Care in Oncology
November 27th 2024A recent Targeted Oncology survey explores the challenges and best practices in transitioning patients with cancer from inpatient to outpatient care, featuring insights from Cristina Gasparetto, MD, on improving these processes.
Read More
